{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:54:23Z","timestamp":1758970463634,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Osteoarthritis (OA) high disability rate will increase as people getting older, and is the most prevalent form of arthritis in the future. This study identified the clinical effects of optimum doses of tanezumab for patients with OA.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> Three electronic databases were searched up until January 15, 2021. The mean difference (MD) or odds ratio (OR) was considered an effect measure. The design-by-treatment interaction model was adopted for network meta-analyses. Analyses were conducted using WinBUGS 1.4.3 and R 4.0.5 software.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> nine publications with 10 studies were included. Compared with placebo in network meta-analysis, except the outcomes of Western Ontario and McMaster Universities Osteoarthritis (WOMAC) stiffness subscale and joints replaced, all dosages of tanezumab in the other effectiveness outcome were superior to placebo, and the difference was statistically significant. However, there was no statistical difference among all different doses of tanezumab. Compared with placebo, except the outcomes of adverse events (AEs) and AEs of abnormal peripheral sensation, all different dosages of tanezumab weren\u2019t superior to placebo in the other effectiveness outcome, and the difference was statistically significant. The 10\u00a0mg of tanezumab with highest SUCRA had the best effect, but it was associated with a higher safety event. Compared with placebo, except the outcomes of WOMAC stiffness subscale and joints replaced, all dosages of tanezumab in the other effectiveness outcome were superior to placebo, and the difference was statistically significant. Compared with placebo, except for the outcomes of AEs and AEs of abnormal peripheral sensation, all dosages of tanezumab in the other effectiveness outcome were superior to placebo, and the difference was statistically significant. Other direct comparisons showed no statistical difference.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study recommended that clinicians should give priority to the treatment of OA patients with a low dose of 2.5\u00a0mg according to the patient\u2019s condition and actual situation. If the effect using tanezumab with 2.5\u00a0mg is not satisfactory, the increase up to 10\u00a0mg should be carefully pondered, because of a more unbalanced risk\/benefit ratio.<\/jats:p>","DOI":"10.3389\/fphar.2021.614753","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T08:20:30Z","timestamp":1623399630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Rui","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Feng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/annrheumdis-2012-203164","article-title":"Efficacy and Safety of Tanezumab Added on to Diclofenac Sustained Release in Patients with Knee or Hip Osteoarthritis: a Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Phase III Randomised Clinical Trial","volume":"73","author":"Balanescu","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2131\/jts.43.1","article-title":"Development of Pain Therapies Targeting Nerve Growth Factor Signal Transduction and the Strategies Used to Resolve Safety Issues","volume":"43","author":"B\u00e9langer","year":"2018","journal-title":"J. Toxicol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","article-title":"Subcutaneous Tanezumab for Osteoarthritis of the Hip or Knee: Efficacy and Safety Results from a 24-week Randomised Phase III Study with a 24-week Follow-Up Period","volume":"79","author":"Berenbaum","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jns.2014.07.028","article-title":"Nerve Safety of Tanezumab, a Nerve Growth Factor Inhibitor for Pain Treatment","volume":"345","author":"Brown","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/art.37950","article-title":"Tanezumab Reduces Osteoarthritic Hip Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial","volume":"65","author":"Brown","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jpain.2012.05.006","article-title":"Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial","volume":"13","author":"Brown","year":"2012","journal-title":"The J. Pain"},{"key":"B7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/pm\/pnw262","article-title":"Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials","volume":"18","author":"Chen","year":"2017","journal-title":"Pain Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrrheum.2013.44","article-title":"Biologic Agents in Osteoarthritis: Hopes and Disappointments","volume":"9","author":"Chevalier","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.semarthrit.2016.12.001","article-title":"Biologic Drugs as Analgesics for the Management of Osteoarthritis","volume":"46","author":"Dimitroulas","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3899\/jrheum.131294","article-title":"Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus Naproxen","volume":"41","author":"Ekman","year":"2014","journal-title":"J. Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s10067-020-05488-4","article-title":"Efficacy and Safety of Tanezumab Administered as a Fixed Dosing Regimen in Patients with Knee or Hip Osteoarthritis: a Meta-Analysis of Randomized Controlled Phase III Trials","volume":"40","author":"Fan","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/art.34385","article-title":"Neuroplasticity of Sensory and Sympathetic Nerve Fibers in a Mouse Model of a Painful Arthritic Joint","volume":"64","author":"Ghilardi","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jrsm.1285","article-title":"A Design-By-Treatment Interaction Model for Network Meta-Analysis and Meta-Regression with Integrated Nested Laplace Approximations","volume":"9","author":"G\u00fcnhan","year":"2018","journal-title":"Res. Syn Meth"},{"unstructured":"Cochrane Handbook for Systematic Reviews of Interventions\n            HigginsJ.\n            GreenS.\n          2011","key":"B14"},{"key":"B15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.39492","article-title":"When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program","volume":"68","author":"Hochberg","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions: Checklist and Explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B17","first-page":"231","article-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use","volume":"48","author":"Author Anonymous","year":"1997","journal-title":"Int. Dig. Health Legis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0157105","DOI":"10.1371\/journal.pone.0157105","article-title":"Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis","volume":"11","author":"Kan","year":"2016","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.joca.2018.12.001","article-title":"Serological Biomarker Profiles of Rapidly Progressive Osteoarthritis in Tanezumab-Treated Patients","volume":"27","author":"Karsdal","year":"2019","journal-title":"Osteoarthritis and Cartilage"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/nejmoa0901510","article-title":"Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee","volume":"363","author":"Lane","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of Direct and Indirect Evidence in Mixed Treatment Comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Statist. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.joca.2011.09.006","article-title":"Preliminary Assessment of the Safety and Efficacy of Tanezumab in Japanese Patients with Moderate to Severe Osteoarthritis of the Knee: a Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study","volume":"19","author":"Nagashima","year":"2011","journal-title":"Osteoarthritis and Cartilage"},{"key":"B23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/17512433.2020.1772052","article-title":"Anti-nerve Growth Factor Antibodies for the Treatment of Low Back Pain","volume":"13","author":"Patel","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical Methods and Numerical Summaries for Presenting Results from Multiple-Treatment Meta-Analysis: an Overview and Tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and Mixed-Treatment Comparison, Network, or Multiple-Treatments Meta-Analysis: many Names, many Benefits, many Concerns for the Next Generation Evidence Synthesis Tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res. Syn. Meth."},{"key":"B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2019.8044","article-title":"Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients with Osteoarthritis of the Hip or Knee","volume":"322","author":"Schnitzer","year":"2019","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-204905","article-title":"Efficacy and Safety of Tanezumab Monotherapy or Combined with Non-steroidal Anti-inflammatory Drugs in the Treatment of Knee or Hip Osteoarthritis Pain","volume":"74","author":"Schnitzer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.joca.2014.10.003","article-title":"A Systematic Review of the Efficacy and General Safety of Antibodies to NGF in the Treatment of OA of the Hip or Knee","volume":"23","author":"Schnitzer","year":"2015","journal-title":"Osteoarthritis and Cartilage"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","article-title":"A Phase III Placebo- and Oxycodone-Controlled Study of Tanezumab in Adults with Osteoarthritis Pain of the Hip or Knee","volume":"154","author":"Spierings","year":"2013","journal-title":"Pain"},{"key":"B30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/jpr.s191297","article-title":"Pooled Analysis of Tanezumab Efficacy and Safety with Subgroup Analyses of Phase III Clinical Trials in Patients with Osteoarthritis Pain of the Knee or Hip","volume":"12","author":"Tive","year":"2019","journal-title":"J. Pain. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/rheumatology\/keq188","article-title":"Angiogenesis and Nerve Growth Factor at the Osteochondral junction in Rheumatoid Arthritis and Osteoarthritis","volume":"49","author":"Walsh","year":"2010","journal-title":"Rheumatology"},{"key":"B32","first-page":"50","article-title":"New Drug Treatments for Osteoarthritis: What Is on the Horizon?","volume":"2","author":"Watt","year":"2017","journal-title":"Eur. Med. J. Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/pm\/pnaa260","article-title":"Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-Analysis of Randomized Phase III Clinical Trials","volume":"18","author":"Yu","year":"2020","journal-title":"Pain Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.mcn.2007.01.005","article-title":"Phosphoinositide-3-kinase and Mitogen Activated Protein Kinase Signaling Pathways Mediate Acute NGF Sensitization of TRPV1","volume":"34","author":"Zhu","year":"2007","journal-title":"Mol. Cell Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.614753\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T08:20:40Z","timestamp":1623399640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.614753\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":34,"alternative-id":["10.3389\/fphar.2021.614753"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.614753","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"article-number":"614753"}}